Eisai, SuperGen release data for Dacogen trial
DUBLIN, Calif. Japanese drug maker Eisai has released data on a late-stage clinical trial of a drug for leukemia, Eisai’s development partner said Wednesday.
SuperGen said that while the injectable drug Dacogen (decitabine) did not show statistically significant superiority in overall survival in elderly patients with acute myeloid leukemia compared over treatments given to patients in the control group, “a trend was evident.”
Based on findings, Eisai plans to submit a regulatory application to the Food and Drug Administration seeking approval for Dacogen as a treatment for elderly patients with AML. The drug already is approved to treat myelodysplastic syndromes.